Middle East and Africa Anticoagulation Therapy Market, By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Testing Devices (In-Office Testing Devices, Analyzers, Reagents and Kits, Home Testing Devices), Services (Testing Services, Consulting), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Industry Trends and Forecast to 2030.
Middle East and Africa Anticoagulation Therapy Market Analysis and Size
The rapid rise in prevalence of arrhythmia, blood vessel thromboembolism and stroke and other cardiovascular diseases such as coronary artery disease across the globe are expected to accelerate the market growth in the forecast period of 2023 to 2030. Furthermore, increasing outpatient anticoagulation therapy, rising acceptance of NOAC’s, growing heparin trade and increasing awareness regarding anti-coagulants therapy among physicians further estimated to cushion the growth of the market.
Data Bridge Market Research analyses that the Middle East and Africa anticoagulation therapy market which was USD 741.97 million in 2022, and is expected to reach USD 1,292.58 million by 2030, and is expected to undergo a CAGR of 7.7% during the forecast period 2023-2030. This indicates that the market value. “Hospitals” dominates the end user segment of the Middle East and Africa anticoagulation therapy market owing to the growing demand for drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Middle East and Africa Anticoagulation Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Testing Devices (In-Office Testing Devices, Analyzers, Reagents and Kits, Home Testing Devices), Services (Testing Services, Consulting), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
|
|
Countries Covered
|
Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa
|
|
Market Players Covered
|
Hikma Pharmaceuticals PLC(U.K.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel),Novartis AG (Switzerland), Eisai Co., Ltd.(Japan),Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Sanofi, Fresenius SE & Co. KGaA (Germany),Fresenius Kabi AG (Germany),Aspen Holdings (South Africa),Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China), Cipla Inc (India),Johnson & Johnson Private Limited. (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Eagle Pharmaceuticals, Inc. (U.S.), Endo International plc (Ireland), Mitsubishi Tanabe Pharma Corporation (Japan), Taro Pharmaceutical Industries Ltd (Israel)
|
|
Market Opportunities
|
|
Market Definition
Anticoagulation therapy is a type of medication which is used in prevention of blood clots formation and to endorse blood vessels open, they generally help to prevent or to reduce blood clot formation/thrombi which further reduces their chances of developing serious conditions such as strokes and heart attacks.
Middle East and Africa Anticoagulation Therapy Market Dynamics
Drivers
- Increasing Prevalence of Cardiovascular Diseases
The cases of chronic blood diseases are growing exponentially and will likely drive the worldwide antiplatelet drugs market. Cardiovascular diseases, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism, are on the rise in the MEA region. These conditions often require anticoagulation therapy to prevent blood clot formation. The rising incidences of cardiovascular diseases is a major factor driving the antiplatelet drugs market's growth rate. In both developed and developing economies, cardiovascular illnesses are the leading cause of death.
According to the Centers for Disease Control and Prevention (CDC), over 800,000 individuals in the United States die each year from stroke and other cardiovascular disorders.
- Rising Number of Geriatric Population
Pharmaceutical companies are investing in research and development to create newer and safer anticoagulant drugs, which is expanding treatment options for patients. Expanding geriatric population worldwide is predicted to favour anticoagulation therapy demand as this population is more prone to heart diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases such as cardiovascular diseases, which can foster the demand for anticoagulation drugs across the globe.
According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 and this number is expected 2.1 billion by 2050.
- Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of Middle East and Africa anticoagulation therapy market is the rising healthcare expenditure which helps in improving its infrastructure. Increasing disposable income in some MEA countries is making anticoagulation therapy more accessible to a broader population.
Furthermore, growing awareness among healthcare professionals and patients about the benefits of anticoagulation therapy in preventing strokes and other thrombotic events which is expected to enhance the market's growth rate.
Opportunity
- Increase in the Number of Research and Development Activities
Pharmaceutical companies are investing in research and development to create newer and safer anticoagulant drugs, which is expanding treatment options for patients. Rising clinical trials and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Middle East and Africa anticoagulation therapy market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
The rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the Middle East and Africa anticoagulation therapy market during the forecast period 2023-2030.
Restraint/Challenge
- High Cost Associated with the Therapy
On the other hand, the high cost associated with the therapy are expected to obstruct the growth rate of market. The cost of anticoagulant medications, especially newer and more advanced drugs, can be a significant barrier to access for many patients in the MEA region, where healthcare affordability remains an issue will challenge the market. Moreover, the high risk of malfunctions like increased bleeding is expected to restrain and further impede the growth rate of market during the forecast period 2023-2030.
This Middle East and Africa anticoagulation therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa anticoagulation therapy market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In October 2019, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved Xarelto (Rivaroxaban) for the prevention of venous thromboembolism (VTE)
- In March 2019, Bristol-Myers Squibb-Pfizer Alliance announced results of Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs) in individuals with non-valvular atrial fibrillation (NVAF) and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI)
Middle East and Africa Anticoagulation Therapy Market Scope
The Middle East and Africa anticoagulation therapy market is segmented on the treatment, therapeutic class, drug type, testing devices, services, route of administration, therapeutic area, procedure, type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Arterial Thromboembolism (AT)
- Stroke
- Others
Therapeutic Class
- Novel Oral Anticoagulants (NOAC)
- Heparin
- Vitamin K Antagonists
- Others
Drug Type
- Bivalirudin
- Dabigatran
- Edoxaban
- Betrixaban
- Rivaroxaban
- Apixaban
- Enoxaparin
- Dalteparin
- Others
Testing Devices
- In-Office Testing Devices
- Analyzers, Reagents and Kits
- Home Testing Devices
Services
- Testing Services
- Consulting
Route of Administration
- Oral
- Parenteral
Therapeutic Area
- Cardiovascular
- Respiratory
- Oncology
- Nephrology
- CNS
- Others
Procedure
- Pre-Surgical Procedures
- Post-Surgical Procedures
- Kidney Dialysis
- Heart Valve Replacement
Type
- Generics
- Branded
End User
- Hospitals
- Clinics
- Homecare
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Middle East and Africa Anticoagulation Therapy Market Regional Analysis/Insights
The Middle East and Africa anticoagulation therapy market is analysed and market size insights and trends are provided by the treatment, therapeutic class, drug type, testing devices, services, route of administration, therapeutic area, procedure, type, end user and distribution channel as referenced above.
The countries covered in the Middle East and Africa anticoagulation therapy market report are Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA).
Saudi Arabia accounted the largest market share for Middle East and Africa anticoagulation therapy market due to developing healthcare sector with increasing medical devices and pharmaceutical products in the country as well as rapid rise in prevalence of arrhythmia, blood vessel thromboembolism and stroke and other cardiovascular diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Middle East and Africa anticoagulation therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Middle East and Africa anticoagulation therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Middle East and Africa anticoagulation therapy market. The data is available for historic period 2015-2020.
Competitive Landscape and Middle East and Africa Anticoagulation Therapy Market Share Analysis
The Middle East and Africa anticoagulation therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Middle East and Africa anticoagulation therapy market.
Some of the major players operating in the Middle East and Africa anticoagulation therapy market are:
- Hikma Pharmaceuticals PLC (U.K.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Novartis AG (Switzerland)
- Eisai Co., Ltd. (Japan)
- Pfizer Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Sanofi, Fresenius SE & Co. KGaA (Germany)
- Fresenius Kabi AG (Germany)
- Aspen Holdings (South Africa)
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China)
- Cipla Inc (India)
- Johnson & Johnson Private Limited. (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH (Germany)
- Bristol-Myers Squibb Company (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Eagle Pharmaceuticals, Inc. (U.S.)
- Endo International plc (Ireland)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Taro Pharmaceutical Industries Ltd (Israel)
SKU-